MENU

Clinical Trials Wide Range of Advanced Treatments

With advanced treatments available through our partnership with neuro-oncology research applications with national consortiums of care, our team of neurosurgical specialists is able to provide a wide range of innovative treatment options. Because of our dedication to research and improving clinical outcomes, Arkansas Children’s is able to offer cutting-edge care when tumors don’t respond to more traditional treatment protocols.

With both surgical and radiation options for the treatment of brain and spinal tumors, our specialists work together to make the best recommendation for treatment based on each individual patient’s needs.

Advancing Care through Innovation and Discovery

We offer new techniques and clinical trials, unique to specific tumors we treat, for an aggressive path of care – providing the skill and experience necessary for the most complex cases. New therapies may be available through our Experimental Therapeutics Program, including:

  • Young Children (less than age 10) with Medulloblastoma or PNET at Diagnosis: Head Start 4 sponsored by the NEXT Consortium - to Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Either Single Cycle (low risk patients) OR Randomization (high risk patients) to Either Single-Cycle or to Three Tandem CYCLES OF Marrow-Ablaytive Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue
  • Ependymoma at Initial Diagnosis (Study ACNS0831) sponsored by the Children's Oncology Group (COG) - a Phase 3 Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
  • Medulloblastoma with WNT pathway Subgroup at Initial Diagnosis (Study ACNS 1422) sponsored by the Children’s Oncology Group (COG) A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
  • Pediatric MATCH Study (Molecular Analysis for Therapy Choice, Study PEC1621) sponsored by the Children’s Oncology Group (COG) A Study of Molecularly-Guided Therapy for Recurrent or Refractory Malignant Brain Tumors
  • Children with Neurofibromatosis Type 1 (NF1) and a Newly Diagnosed Optic Pathway Tumor (Study Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma) sponsored by Children’s Tumor Foundation (CTF) to Follow Patients with Newly Diagnosed Optic Pathway Tumors to Establish the Natural History and Evaluate MRI and Optical Coherence Tomography (OCT) Techniques in the Evaluation of These Patients
  • Relapsed or Refractory Medulloblastoma (Study ONC-403-001) sponsored by Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) - a Phase 1 Study of TB-403 (a Humanized Monoclonal Antibody Against Placental Growth Factor (PlGF)) in Pediatric Subjects with Relapsed or Refractory Medulloblastoma
  • The pan-ERBB inhibitor Neratinib in Previously Treated Solid and Brain Tumors sponsored by Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) – a Phase I Study for recurrent or refractory solid brain tumors including:
    • All malignant brain tumors at recurrence or disease progression
  • MEK Inhibitor Cobimetnib in Previously Treated Solid Tumors (Study G029665) sponsored by Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) – a Phase 2 Study for Low-Grade Gliomas

Contact Us for More Information

If you have any questions or need more information about whether one of these clinical trials may be available for your child, please contact Catherine Redinger BSN, RN, CPHON at 501-364-4290 or by email at redingercatherinel@uams.edu.